Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.www.incyte.com
6
MENTIONS
3
EPISODES
2
PODCASTS
Search complete. 6 mentions across 3 episodes found for "Incyte".
Sep 15, 2026
Steve UsdinPANELIST
So far, there's no indication that they're gonna succumb to that pressure, and we can circle back to that, but first, a couple of other things that we learned since last week's podcast.
Steve UsdinPANELIST
They didn't participate in the White House press conference and didn't issue a press release, but Incyte has signed some kind of MFN deal with the Trump administration.
Steve UsdinPANELIST
They described it in an SEC filing, saying they'd agreed to give state Medicaid programs access to Jakafi and Jakafi XR at prices aligned with an international reference price.
Steve UsdinPANELIST
I heard that Incyte wasn't at the White House because unlike the pharmas that did MFN deals and the biotech companies, it hasn't made any commitment to tie future launches to an MFN price.
Steve UsdinPANELIST
The company didn't respond to my request for comment, so this is my supposition and things that I heard secondhand, but it is consistent with the SEC release.
Steve UsdinPANELIST
BridgeBio, which was at the White House, stated in a press release that it doesn't expect to be subject to future pricing mandates.
Steve UsdinPANELIST
But first, a couple of other things that we learned since last week's podcast.
Steve UsdinPANELIST
They didn't participate in the White House press conference and didn't issue a press release, but Incyte has signed some kind of MFN deal with the Trump administration.
Steve UsdinPANELIST
They described it in an SEC filing, saying they'd agreed to give state Medicaid programs access to Jakafi and Jakafi XR at prices aligned with an international reference price.
Steve UsdinPANELIST
I heard that Incyte wasn't at the White House because unlike the pharmas that did MFN deals and the biotech companies, it hasn't made any commitment to tie future launches to an MFN price.
Steve UsdinPANELIST
The company didn't respond to my request for comment, so this is my supposition and things that I heard secondhand, but it is consistent with the SEC release.
Steve UsdinPANELIST
BridgeBio, which was at the White House, stated in a press release that it doesn't expect to be subject to future pricing mandates.
Frazier KansteinerHOST
And again, this is stemming from essentially the CMS agreeing not to label Opsoluro as a line extension of the oral JAK inhibitor, Jakafi, when determining its rebate.
Frazier KansteinerHOST
And Incyte says that it also expects this to deliver an additional benefit of about $40 million to $50 million for the rest of the year.
Frazier KansteinerHOST
That being said, Incyte's CEO was a little bit cautious about the long-term benefits from this, and he said that he continues to see the pricing and reimbursement environment as being dynamic and kind of needing to continue to focus on expanding access in order to make the most out of this drug.
James WaldronGUEST
Well, that's a really fascinating roundup of some upcoming blockbusters.
James WaldronGUEST
While we're on the topic of potential blockbusters, I wondered if I could do one more plug for my interview with Novo Nordisk's Chief Financial Officer, Carsten Munk Knudsen.